Angiographic and clinical outcomes of late total occlusion versus treatment failure without late total occlusion in patients after intracoronary radiation therapy for in-stent restenosis

2004 ◽  
Vol 94 (12) ◽  
pp. 1551-1554 ◽  
Author(s):  
Roswitha Wolfram ◽  
Edouard Cheneau ◽  
Gary S. Mintz ◽  
Augusto D. Pichard ◽  
Lowell F. Satler ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Treatment Failure ◽  
Clinical Outcomes ◽  
Total Occlusion ◽  
Stent Restenosis ◽  
Versus Treatment ◽  
In Stent Restenosis

scholarly journals Age is an important predictor of clinical outcomes following intracoronary radiation therapy for in-stent restenosis

2002 ◽  
Vol 39 ◽  
pp. 66
Author(s):  
Andrew E. Alani ◽  
Edouard Cheneau ◽  
R.Larry White ◽  
Bill G. Bass ◽  
Augusto D. Pichard ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Clinical Outcomes ◽  
Important Predictor ◽  
Stent Restenosis ◽  
In Stent Restenosis

scholarly journals A comparison of procedural success rate and long-term clinical outcomes between in-stent restenosis chronic total occlusion and de novo chronic total occlusion using multicenter registry data

2019 ◽  
Vol 109 (5) ◽  
pp. 628-637 ◽  
Author(s):  
Seung Hun Lee ◽  
Jae Young Cho ◽  
Je Sang Kim ◽  
Hyun Jong Lee ◽  
Jeong Hoon Yang ◽  
...  
Keyword(s):  
Success Rate ◽  
Clinical Outcomes ◽  
Chronic Total Occlusion ◽  
De Novo ◽  
Drug Eluting Stent ◽  
Total Occlusion ◽  
Stent Restenosis ◽  
Procedural Success ◽  
In Stent Restenosis

Abstract Background There have been little data about outcomes of percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) chronic total occlusion (CTO) in the drug eluting stent (DES) era. This study aimed to compare the procedural success rate and long-term clinical outcomes of ISR CTO and de novo CTO. Methods and results Patients who underwent PCI for ISR CTO (n = 164) versus de novo CTO (n = 1208) were enrolled from three centers in Korea between January 2008 and December 2014. Among a total of ISR CTO, a proportion of DES ISR CTO was 79.3% (n = 130). The primary outcome was major adverse cardiac events (MACEs); a composite of all-cause death, non-fatal myocardial infarction (MI), or target lesion revascularization (TLR). Following propensity score-matching (1:3), the ISR CTO group (n = 156) had a higher success rate (84.6% vs. 76.0%, p = 0.035), mainly driven by high success rate of PCI for DES ISR CTO (88.6%), but showed a higher incidence of MACEs [hazard ratio (HR): 2.06; 95% confidence interval (CI) 1.37–3.09; p < 0.001], mainly driven by higher prevalence of MI [HR: 9.71; 95% CI 2.06–45.81; p = 0.004] and TLR [HR: 3.04; 95% CI 1.59–5.81; p = 0.001], during 5 years of follow-up after successful revascularization, as compared to the de novo CTO group (n = 408). Conclusion The procedural success rate was higher in the ISR CTO than the de novo CTO, especially in DES ISR CTO. However, irrespective of successful revascularization, the long-term clinical outcomes for the ISR CTO were significantly worse than those for the de novo CTO, in terms of MI and TLR. Graphic abstract

Sign in / Sign up

Export Citation Format

Share Document